Olorofim Trial Meets Mortality Goal Against Standard Antifungal in Aspergillosis
In the phase 3 OASIS trial, 23.8% of patients taking oral olorofim died from any cause by day 42, compared with 24.3% of those receiving AmBisome plus standard care for invasive aspergillosis unsuitable for azole therapy. Olorofim is an investigational orotomide that blocks fungal dihydroorotate dehydrogenase and pyrimidine synthesis, including against azole-resistant Aspergillus. The manufacturer plans to resubmit a New Drug Application to the FDA by the end of 2026.
Olorofim is an experimental oral antifungal in a new class called orotomides. It acts by shutting down a fungal enzyme needed for pyrimidine production, a mechanism that also appears active against Aspergillus strains resistant to azoles.
In the phase 3 OASIS study, researchers compared olorofim with AmBisome plus usual care in people with invasive aspergillosis who could not receive azole therapy. By day 42, all-cause death occurred in 23.8% of olorofim recipients and 24.3% of the comparator group, meeting the trial’s noninferiority goal. Olorofim remains unapproved; F2G intends to resubmit an FDA New Drug Application by late 2026.
If approved, olorofim could broaden options for patients with invasive aspergillosis, particularly those who cannot tolerate or do not respond to azoles. An oral therapy may simplify some treatment pathways and may help clinicians manage azole-resistant infections. Its impact would depend on regulatory review, availability, cost, and real-world safety data, so the trial result may be most relevant to specialists, hospital pharmacies, and patients facing limited antifungal choices.